Joacilda da Conceição Nunes1, Georgia Véras de Araujo2, Marcelo Tavares Viana3, Emanuel Sávio Cavalcanti Sarinho4,5. 1. Department of Genetics and Pediatrics, Federal University of Paraíba, João Pessoa, PB, Brazil. 2. Research Center for Allergy and Clinical Immunology, Federal University of Pernambuco, Av. Prof. Moraes Rêgo, s/n, University City, Recife, PE, CEP 50670-901, Brazil. georgiaveras@uol.com.br. 3. Department of Biostatistics in Science of Health, Federal University of Pernambuco, Recife, PE, Brazil. 4. Research Center for Allergy and Clinical Immunology, Federal University of Pernambuco, Av. Prof. Moraes Rêgo, s/n, University City, Recife, PE, CEP 50670-901, Brazil. 5. Department of Pediatrics, Federal University of Pernambuco, Recife, PE, Brazil.
Abstract
BACKGROUND: Several factors related to the immune system, such as a history of allergies and virus infections, may be associated with acute lymphoblastic leukemia (ALL). The purpose of this study was to analyze whether the presence of atopic diseases and previous infection with parvovirus B19 and Epstein-Barr virus (EBV) are associated with the development of ALL. METHODS: This case-control study was performed in two tertiary hospitals located in northeastern Brazil. The study population included 60 patients who were diagnosed with non-T-cell ALL using myelogram and immunophenotyping and 120 patients in the control group. Atopy was evaluated via a parent questionnaire and medical records. Total immunoglobulin (Ig)E and IgG levels of parvovirus B19 and EBV were measured in the serum. Logistic regression was performed to assess the association between variables and odds of ALL. RESULTS: We identified a significant inverse association between rhinitis, urticaria and elevated IgE serum levels with ALL. A history of parvovirus B19 infection showed a significant association with this type of cancer [OR (95 % CI) 2.00 (1.94-4.26); P = 0.050]. In logistic regression, the presence of atopy was a protective factor [OR (95 % CI) 0.57 (0.38-0.83); P = 0.004], and the presence of IgG for parvovirus B19 was an important risk factor for ALL [OR (95 % CI) 2.20 (1.02-4.76); P = 0.043]. CONCLUSIONS: These results suggest that atopic diseases and elevated total IgE levels are associated with a potential protective effect on the development of ALL. Previous infection with parvovirus B19 contributed to ALL susceptibility.
BACKGROUND: Several factors related to the immune system, such as a history of allergies and virus infections, may be associated with acute lymphoblastic leukemia (ALL). The purpose of this study was to analyze whether the presence of atopic diseases and previous infection with parvovirus B19 and Epstein-Barr virus (EBV) are associated with the development of ALL. METHODS: This case-control study was performed in two tertiary hospitals located in northeastern Brazil. The study population included 60 patients who were diagnosed with non-T-cell ALL using myelogram and immunophenotyping and 120 patients in the control group. Atopy was evaluated via a parent questionnaire and medical records. Total immunoglobulin (Ig)E and IgG levels of parvovirus B19 and EBV were measured in the serum. Logistic regression was performed to assess the association between variables and odds of ALL. RESULTS: We identified a significant inverse association between rhinitis, urticaria and elevated IgE serum levels with ALL. A history of parvovirus B19 infection showed a significant association with this type of cancer [OR (95 % CI) 2.00 (1.94-4.26); P = 0.050]. In logistic regression, the presence of atopy was a protective factor [OR (95 % CI) 0.57 (0.38-0.83); P = 0.004], and the presence of IgG for parvovirus B19 was an important risk factor for ALL [OR (95 % CI) 2.20 (1.02-4.76); P = 0.043]. CONCLUSIONS: These results suggest that atopic diseases and elevated total IgE levels are associated with a potential protective effect on the development of ALL. Previous infection with parvovirus B19 contributed to ALL susceptibility.
Authors: T Zuberbier; R Asero; C Bindslev-Jensen; G Walter Canonica; M K Church; A M Giménez-Arnau; C E H Grattan; A Kapp; M Maurer; H F Merk; B Rogala; S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; H Schünemann; P Staubach; G A Vena; B Wedi Journal: Allergy Date: 2009-10 Impact factor: 13.146
Authors: M S Linet; L D McCaffrey; R L Humphrey; R Brookmeyer; M L Van Natta; J M Tielsch; W B Bias; J A Markowitz; S C Kravitz; M Szklo Journal: J Natl Cancer Inst Date: 1986-08 Impact factor: 13.506
Authors: Jeremiah Hwee; Christopher Tait; Lillian Sung; Jeffrey C Kwong; Rinku Sutradhar; Jason D Pole Journal: Br J Cancer Date: 2017-10-24 Impact factor: 7.640